Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Saccharomyces cerevisiae strain:BY4742 | breed:10 mg CA

ABSTRACT: Saccharomyces cerevisiae strain:BY4742 | breed:10 mg CA Raw sequence reads

PROVIDER: PRJNA1045720 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Saccharomyces cerevisiae strain:BY4742 | breed:10 mg/L SAA

Project description:Saccharomyces cerevisiae strain:BY4742 | breed:10 mg/L SAA Raw sequence reads

| PRJNA1045725 | ENA

Saccharomyces cerevisiae strain:BY4742 | breed:100 mg RA

Project description:Saccharomyces cerevisiae strain:BY4742 | breed:100 mg RA Raw sequence reads

| PRJNA1045718 | ENA

Saccharomyces cerevisiae strain:BY4742 | breed:200 mg/L SAA

Project description:Saccharomyces cerevisiae strain:BY4742 | breed:200 mg/L SAA Raw sequence reads

| PRJNA1045732 | ENA

Saccharomyces cerevisiae strain:BY4742 | breed:100 mg/L SAA

Project description:Saccharomyces cerevisiae strain:BY4742 | breed:100 mg/L SAA Raw sequence reads

| PRJNA1045729 | ENA

Saccharomyces cerevisiae strain:BY4742 | breed:200 mg/L caffeic acid

Project description:Saccharomyces cerevisiae strain:BY4742 | breed:200 mg/L caffeic acid Raw sequence reads

| PRJNA1045722 | ENA

Saccharomyces cerevisiae strain:BY4742 | breed:100 mg/L Caffeic acid

Project description:Saccharomyces cerevisiae strain:BY4742 | breed:100 mg/L Caffeic acid Raw sequence reads

| PRJNA1045721 | ENA

Saccharomyces cerevisiae strain:BY4742 | breed:Eukaryotic Breed

Project description:Saccharomyces cerevisiae strain:BY4742 | breed:Eukaryotic Breed Raw sequence reads

| PRJNA1045553 | ENA

Saccharomyces cerevisiae strain:BY4742 | breed:LB

Project description:Saccharomyces cerevisiae strain:BY4742 | breed:LB Raw sequence reads

| PRJNA1045733 | ENA

Saccharomyces cerevisiae strain:BY4742

Project description:Saccharomyces cerevisiae BY4742 genome sequencing

| PRJNA346640 | ENA

Ca:Mg Ratio and Cognitive Function

Project description:Between 2000 and 2015, mortality due to Alzheimer’s disease (AD) increased by 123%. No drugs have yet been approved to stop or slow the progression of AD. A delay of five years in the expression of AD would reduce the incidence rate by half. Thus, it is critical to develop novel prevention strategies to delay the onset of this common disease. As an ancillary study conducted within a precision-based randomized trial (R01CA149633; PI, Dai & Yu]"), the investigators reduced Ca:Mg ratios to 2.3 through 3-month personalized Mg supplementation among those who consumed high Ca:Mg ratio diet, but otherwise in good general health. The investigators test the hypothesis that actively reducing the Ca:Mg ratio among those aged >65 years who consume high Ca:Mg ratio diets improves cognitive function compared to the placebo arm. The investigators further conduct molecular epidemiologic studies to understand the molecular mechanisms.

| 2324458 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data